Lesson plan

QMPSB

QMPSB is an arylsulfonamide-based synthetic cannabinoid that has been sold as a designer drug. QMPSB was first discovered by Nathalie Lambeng and colleagues in 2007. It acts as a full agonist of the CB 1 receptor and CB 2 receptor with K i values of 3 nM and 4 nM, respectively. Many related derivatives were subsequently produced, with the main focus of this work being to increase selectivity for the non-psychoactive CB 2 receptor. This work led on from an earlier series of sulfamoyl benzamide derivatives for which a patent was filed in 2004. The quinolin-8-yl ester motif of QMPSB led to the discovery of other designer cannabinoids such as PB-22 and BB-22.

Back to article

Article summary

QMPSB is an arylsulfonamide-based synthetic cannabinoid that has been sold as a designer drug. QMPSB was first discovered by Nathalie Lambeng and colleagues in 2007. It acts as a full agonist of the CB 1 receptor and CB 2 receptor with K i values of 3 nM and 4 nM, respectively. Many related derivatives were subsequently produced, with the main focus of this work being to increase selectivity for the non-psychoactive CB 2 receptor. This work led on from an earlier series of sulfamoyl benzamide derivatives for which a patent was filed in 2004. The quinolin-8-yl ester motif of QMPSB led to the discovery of other designer cannabinoids such as PB-22 and BB-22.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.